Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Lifted by Clean Yield Group

Clean Yield Group raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 15.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,909 shares of the medical equipment provider's stock after buying an additional 7,263 shares during the quarter. Clean Yield Group's holdings in Hologic were worth $3,268,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. grew its position in Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after acquiring an additional 1,606 shares in the last quarter. Groupama Asset Managment boosted its stake in Hologic by 63.4% in the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock valued at $3,918,000 after acquiring an additional 21,037 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in Hologic during the 4th quarter worth approximately $4,215,000. Signaturefd LLC raised its position in Hologic by 34.5% in the 4th quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock valued at $212,000 after purchasing an additional 754 shares during the last quarter. Finally, Brevan Howard Capital Management LP raised its holdings in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock valued at $1,401,000 after buying an additional 8,960 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HOLX. Evercore ISI lowered their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Raymond James reiterated an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Royal Bank of Canada cut their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of "Hold" and an average price target of $77.42.

Hologic Stock Performance

Shares of Hologic stock traded down $0.57 during trading hours on Wednesday, reaching $64.57. The company's stock had a trading volume of 1,831,657 shares, compared to its average volume of 2,304,440. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company's 50 day simple moving average is $58.42 and its 200 day simple moving average is $65.16. The stock has a market cap of $14.39 billion, a P/E ratio of 20.37, a price-to-earnings-growth ratio of 2.14 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.03 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.